2022年3月7日 · Exatecan (DX 8951f) is another intravenous topoisomerase 1 inhibitor with encouraging activity recently reported [24]. In previously treated and untreated patients …

Exatecan is a potent topoisomerase I inhibitor, with an IC 50 of 0.975 μg/mL. Exatecan Mesylate (DX-8951f) significantly inhibits the proliferation of several cancer cell lines, with mean GI 50 s …

2016年10月20日 · Exatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others. The next evolution of …

Exatecan (Exa) is a very potent inhibitor of topoisomerase I and anticancer agent. It has been intensively studied as a single agent, a large macromolecular conjugate and as the payload …

Exatecan is a pyranoindolizinoquinoline. Exatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others. …

It is of high interest that two additional water soluble derivatives have been developed: exatecan, which was found to be a promising anticancer agent and lurtotecan, recently introduced in …

Exatecan induces cellular TOP1ccs and induces TOP1 degradation at nanomolar concentrations. To confirm the potency of exatecan as a TOP1 poison, we examined the level of DNA-trapped …

Exatecan (DX-8951f), a new hexacyclic camptothecin analogue, is a second-generation topoisomerase inhibitor that prevents rapidly dividing cells from replicating by interrupting DNA …

Exatecan is a potent drug derived from camptothecin, featuring a modified structure with enhanced membrane permeability and cell penetration ability. It shows cytotoxic activity in …

Exatecan has completed Phase I clinical development on a broad range of schedules and is currently undergoing more focused disease-directed Phase II and Phase III evaluations.